Description
The secretion of the cardiac hormone BNP-32 is increased considerably in patients with congestive heart failure, successful medical treatment of this condition will result in a decrease. Yandle et al. described a method for determining hBNP in human plasma. Effects of hBNP infusion in humans have been described by Holmes et al and La Villa et al. BNP is an important biomarker in the diagnosis of heart diseases. Additionally, BNP-32 may act as a neuropeptide. BNP-32 exerts strong lipolytic effects in humans.
